ICER’s Unsupported Price Increase Report: Unfit for Policymaking White Paper ICER’s Unsupported Price Increase Report: Unfit for Policymaking Since 2019, the Institute for Clinical and Economic Review (ICER) has published an annual Unsupported…Certara2023年7月25日
Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program Case Study 薬物動態モデリングおよび科学的コミュニケーションの専門性を活用することで、サルコイドーシス治療薬開発プログラムの前進に貢献 Certara's support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make…Certara2023年6月1日
Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease Case Study Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease RedHill Biopharma Ltd., a specialty biopharmaceutical company, developed RHB-204, a treatment for MAC, and needed…Certara2023年5月9日
Using MBMA to run virtual “head-to-head trials” Case Study MBMAを用いた仮想的な「直接比較試験」の実施 Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…Certara2023年4月21日
Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial Case Study Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…Certara2023年4月17日
Using Real World Evidence to Inform Treatment Guidelines Case Study Using Real World Evidence to Inform Treatment Guidelines Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…Certara2023年4月5日
Using Real Word Evidence to Enhance Drug Development Case Study Using Real Word Evidence to Enhance Drug Development Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…Certara2023年4月5日
Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another Case Study 希少疾患からの臨床データを活用して、他の疾患の医薬品承認をサポート Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…Certara2022年6月1日
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease Blog A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…Certara2021年12月15日
Dose Optimization Using Population PK for an Orphan Drug Case Study ノーベルファーマ社、希少疾患用治療薬開発への挑戦 RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…Certara2021年11月17日